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Failure of sulfa or sulfone prophylaxis is associated
with mutations in Pneumocystis carinii gene coding for
dihydropteroate synthase (DHPS). The DHPS genotype
was analyzed in AIDS patients who had two separate
episodes of P. carinii pneumonia. The results suggest that
DHPS mutations can be selected de novo within patients
by the pressure of a sulfa or sulfone drug.
C
o-trimoxazole, the antifolate drug combination of
trimethoprim and sulfamethoxazole, is the drug of
choice for the prophylaxis and treatment of Pneumocystis
carinii pneumonia (PCP), a life-threatening disease in
immunosuppressed patients. Trimethoprim is an inhibitor
of dihydrofolate reductase, whereas sulfamethoxazole
inhibits dihydropteroate synthase (DHPS). The antipneu-
mocystis activity is believed to be due mainly to sul-
famethoxazole (1). Dapsone is a sulfone drug, also fre-
quently used, that targets DHPS. Widespread use of sulfa
and sulfone drugs to prevent and treat PCP in recent years
has correlated with an increase of the prevalence of muta-
tions in the gene coding for DHPS (2,3). The most frequent
DHPS mutations occur at nucleotide positions 165 and
171, which lead to an amino acid change at positions 55
(Thr to Ala) and 57 (Pro to Ser). These mutations are locat-
ed in the sulfa-binding site and may appear as either a sin-
gle or double mutation in the same isolate. Similar muta-
tions in other microbial pathogens confer sulfa resistance
(4,5). In P. carinii, DHPS mutations are associated with
failure of sulfa or sulfone prophylaxis (1,6) and decreased
survival of the patient at 3 months after PCP (2). However,
patients harboring P. carinii types with DHPS mutations
are most often successfully treated with high-dose co-tri-
moxazole (6). Because a standardized culture system for P.
carinii does not exist, the level of sulfa resistance con-
ferred by these mutations cannot be determined with in
vitro susceptibility tests. A key issue is whether the recent
emergence of DHPS mutations is a result of P. carinii
transmission between patients or arises from selection
within patients by the pressure of a sulfa or sulfone drug,
two possibilities that are not mutually exclusive. To inves-
tigate the latter possibility, we analyzed patients who had
had two separate episodes of PCP.
The Study 
P. carinii DNA was extracted from bronchoalveolar
lavage specimens by using the Qiamp Blood Kit (QIA-
GEN GmbH, Hilden, Germany). Bronchoalveolar lavage
specimens from 13 patients with recurrent PCP episodes
were collected from four European hospitals (Lyon,
France; Copenhagen, Denmark; Lausanne, Switzerland;
and La Chaux-de-Fonds, Switzerland). To determine the
prevalence of the different P. carinii molecular types, we
analyzed bronchoalveolar lavage specimens from 310 PCP
patients from two Swiss hospitals (Lausanne, 111 patients;
Zurich, 64 patients) and Lyon’s hospital (135 patients).
Specific information on demographic and clinical charac-
teristics, chemoprophylaxis, and treatment regimens were
obtained from the medical charts. P. carinii infecting
humans (now named P. jiroveci [7]) was typed by using the
multilocus method developed in our laboratory as previ-
ously described (8–10). In this method, four variable
regions of the P. carinii genome are amplified by poly-
merase chain reaction (PCR), followed by the detection of
polymorphisms using single-strand conformation poly-
morphism (SSCP). AP. carinii type is defined by a combi-
nation of four alleles corresponding to the four genomic
regions. If a specimen harbored two alleles of one or more
of the four genomic regions, the patient was considered to
be co-infected with two or more P. carinii types (9). This
typing system has been validated and the stability of its
markers assessed; its index of discriminatory power has
been estimated to be 0.93 (10). The full length of the
DHPS gene was amplified by PCR as described previous-
ly (1). PCR products (765 bp) were cloned, and both
strands were sequenced (5 clones per sample). The five
clones had identical sequences for all samples, except for
those from patients 3 and 4, which contained a mixture of
DHPS sequences. 
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were analyzed (Table). All patients had recovered
between episodes. The intervals between the episodes
ranged from 4 to 25 months. All patients had AIDS and
all, except patients 8 and 9, were men, with a median age
of 35 (range 23–51) and median CD4 cell count of 9.5
cells/µL (range 0–98). Some patients were co-infected
with two different P. carinii types, as shown by PCR-
SSCP multilocus typing method (patients 4, 5, 8, 11, and
13) or DHPS genotyping (patients 3 and 4). In seven
(54%) patients (patients 1–7), the same PCR-SSCP type
was observed in both episodes of PCP; six (46%) patients
(patients 8–13) had different types in the first and second
episodes. This rate of genotype switch is similar to that
reported in previous studies, in which such a change was
observed in approximately half of recurrent episodes
(11–14). The importance of a genotype switch remains
uncertain. Indeed, the switch might be due to a de novo
infection or to the reactivation of a genotype not detect-
ed in the first episode because of the compartmentaliza-
tion of different co-infecting P. carinii types in the lungs
(15).
A second episode of PCP could result either from reac-
tivation of organisms that caused the first episode or from
de novo infection with a new P. carinii type acquired from
an exogenous source. In seven patients (patients 1–7),
reactivation was strongly suggested by the detection of
identical SSCP types in both episodes of PCP. An alterna-
tive explanation could be de novo infection in the second
episode by the same P. carinii PCR-SSCP type as that
which caused the first episode. However, the prevalence of
the types observed in the seven “reactivation” cases was
low in Lyon and Switzerland during the study period
(types no. 2, 5, and 7 represented 7%, 6%, and 10%,
respectively, of Lyon’s isolates; type 6 represented only
3.5% of the Swiss isolates [Figure]). Thus, reinfection with
these specific types was unlikely. All Danish patients (1, 3,
and 6) were infected with type 6. Although no prevalence
data for SSCP genotypes in Denmark are available, no
indication of possible contact between these patients, over-
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Table. Pneumocystis carinii DHPS and PCR-SSCP genotyping in AIDS patients with recurrent pneumonia  
Patient no.  City
b  Age 
Date of episode 1/ 
date of episode 2/ 
interval (mo)  CD4/mm
3 
Prophylaxis at  
PCP episode
c  Treatment 
Outcome of 
treatment 
P. carinii PCR-
SSCP type  DHPS genotype
d 
1  Co  29  7/16/1993  9  D  CO → P
e  Success  6  WT 
      6/8/1994 (11)  0  P  CO  Success  6  M1 
2  Ly  36  1/31/1994  58  D  A  Success  7  M2 
      5/18/1995 (16)  16  CO  A  Success  7  M3 
3  Co  51  8/19/1994  0  No  CO → C/P
e  Success  6  WT/M1 
      12/23/1994 (4)  0  P  T  Success  6  M1 
4  Ly  32  11/23/1994  75  No  CO  Success  2, 5  WT/M3 
      3/23/1995 (4)  35  No  CO  Death
f  2, 5  M3 
5  Ly  28  4/19/1995  70  No  A  Success  7, 8  WT 
      3/1/1996 (11)  98  CO  P  Success  7  M3 
6  Co  35  11/16/1995  2  D  P → CO
e  Success  6  M1 
      5/6/1996 (6)  1  D  CO  Success  6  M1 
7  CF  41  2/3/1998  7  CO  P  Success  6  M3 
      7/22/1998 (5)  7  P  C/P  Success  6  M3 
8  La  28  11/24/1990  53  No  T  Success  6, 10  WT 
      7/29/1991 (8)  18  No  CO  Success  7  WT 
9  Co  25  12/8/1992  0  No  CO  Success  5  WT 
      11/5/1993 (11)  0  No  CO  Success  7  WT 
10  Co  35  3/22/1993  10  No  CO → P
e  Success  18  WT 
      10/28/1994 (7)  0  P  CO → P
e  Death
f  6  WT 
11  Ly  23  3/30/1994  22  No  CO → A
e  Success  4, 7  M3 
      3/28/1995 (12)  26  P  D+T → A
e  Success  5  M3 
12  Ly  46  9/21/1994  61  No  CO  Success  15  WT 
      10/21/1996 (25)  16  P  P+A  Success  3  WT 
13  Ly  43  10/12/1994  50  No  CO  Success  1, 2  M2 
      3/25/1996 (17)  5  PM/SD  P+A  Success  1, 3  M2 
aPCP, Pneumocystis carinii pneumonia; DHPS, dihydropteroate synthase; PCR, polymerase chain reaction; SSCP, single-strand conformation polymorphism. 
bCo, Copenhagen (Denmark); CF, La Chaux-de-Fonds (Switzerland); La, Lausanne (Switzerland); Ly, Lyon (France). 
cA, atovaquone; CO, cotrimoxazole; C/P, clindamycin/primaquine; D, dapsone; D+T, dapsone and trimethoprim; P, pentamidine; P+A, pentamidine and atovaquone;  
PM/SD (pyrimethamine/sulfadoxine inhibitors of dihydrofolate reductase (DHFR) and DHPS, respectively); T, trimetrexate (an inhibitor of DHFR). 
dWT, wild type (Thr55 Pro57); M1, mutant 1 (Ala55 Pro57); M2, mutant 2 (Thr55 Ser57); M3, mutant 3 (Ala55 Ser57 double mutant). 
eSwitch of molecules because of toxicity for patients 3, 6, and 11 and because of toxicity and treatment failure for patients 1 and 10. 
fCaused by PCP. lap in hospitalization dates, or similar zip codes for home
address suggested transmission of type 6 between these
patients.
Achange of P. carinii DHPS genotype between the two
episodes was observed in three reactivation cases, either
from wild type in the first episode to DHPS mutations in
the second one (patients 1 and 5) or from DHPS with a sin-
gle mutation (at position 57) in the first episode to a dou-
ble mutation in the second one (patient 2). In two patients
(3 and 4), the DHPS mutant strain was selected out of a
mixture of wild-type and DHPS mutant strains. Because
both episodes of each patient were caused by the same P.
carinii types and because all patients received co-trimoxa-
zole or dapsone as treatment, maintenance therapy, or
both, these results strongly suggest that selection of P.
carinii DHPS mutations occurred within the patients. The
results of tests on patients 3 and 4 isolates highlight the
fact that some patients may harbor genetically different
strains of P. carinii and that the mutant strain may be read-
ily selected when drug pressure is exerted. In the two
remaining patients (6 and 7), the P. carinii DHPS mutant
found in the bronchoalveolar lavage specimen from the
second episode was already present in the first episode.
The wild-type DHPS allele was more frequently
observed in the six reinfection cases than in the reactiva-
tion cases (8 wild-type alleles among 12 genotypes versus
4 among 16, Table). This finding is probably related to the
fact that, with the exception of the second episode of
patient 13, patients who were reinfected had no prophylax-
is or did not receive sulfa drugs for prophylaxis. 
In all the second episodes caused by reactivation,
mutant DHPS strains were observed (7/7), compared to
only two of six second episodes caused by reinfection
(Table). This observation suggests an association between
mutant DHPS and second episodes attributable to reactiva-
tion (p<0.02, Fisher exact test).
Conclusions
Our study suggests that P. carinii DHPS mutants may
be selected in vivo (within a given patient) under the pres-
sure of co-trimoxazole or dapsone and that DHPS muta-
tions may be associated with reactivation of P. carinii.
Whether DHPS mutations are induced by the pressure of
the drug or preexisting and selected out by the pressure of
the drug remains to be determined. Physicians should be
alert to the increased risk for drug resistance during recur-
rence of PCP infection, although the impact of DHPS
mutations on retreatment with sulfa or sulfone drugs
remains to be determined. De novo selection of P. carinii
DHPS strongly favors the hypothesis that P. carinii is
developing sulfa and sulfone resistance.
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